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The enzymes of the cytochrome P450 superfamily play a critical role in phase I drug metabolism. Among them, CYP2C9 
and CYP2C19 are clinically important, as they can mediate severe toxicity, therapy failure, and increased susceptibility 
to cancer and other diseases caused by chemicals. The aim of this study was to determine the prevalence of pharmacologically 
most important allelic variants of the CYP2C9 and CYP2C19 genes in the general population of the Republic of Srpska 
(Bosnia and Herzegovina) and to compare them with other populations. For this purpose we determined the genotype 
profile and allele frequency of 216 randomly selected healthy volunteers using real-time polymerase chain reaction (RT-
PCR). The prevalence of the CYP2C9 *2 and *3 alleles was 13.6 and 7.4 %, respectively. Based on these frequencies, of 
the 216 participants four (1.86 %) were predicted to be poor metabolisers, 78 (36.11 %) intermediate, and the remaining 
134 (62.03 %) normal metabolisers. Based on the prevalence of CYP2C19 *2 and *17 variants – 16.2 and 20.4 %, 
respectively – nine (4.17 %) were predicted to be poor, 57 (26.39 %) rapid, and nine (4.17 %) ultra-rapid metabolisers. 
We found no significant differences in allele frequencies in our population and populations from other European countries. 
These findings suggest that genetically determined phenotypes of CYP2C9 and CYP2C19 should be taken into consideration 
to minimise individual risk and improve benefits of drug therapy in the Republic of Srpska.
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The cytochrome P450 (CYP) superfamily consists of 
enzymes with highly diverse roles in the metabolism of 
drugs, fatty acids, steroids, and xenobiotics (1, 2). Their 
genetic variants, single nucleotide polymorphisms (SNPs) 
in particular, can lead to therapy failure, severe toxicity, 
and increased susceptibility to cancer and other diseases 
caused by chemicals (3). CYPs make about 80 % of all drug 
metabolising enzymes (DMEs), most notably those 
participating in phase I metabolism, such as flavin-
containing monooxygenases, epoxide hydrolases, and many 
other oxidising, reducing, and hydrolysing enzymes (4).
Bearing in mind various types of mutation caused by 
SNPs, genotyping the most relevant CYP enzymes could 
identify patients at risk of developing adverse drug reactions 
and increase treatment safety and efficiency (3). In this 
respect, CYP enzymes CYP2C9 and CYP2C19 are among 
clinically most relevant, as they metabolise about 20–30 % 
of all drugs (5). CYP2C9 metabolises over 100 drugs or 
about 15 % of all drugs in current use (6, 7) including oral 
anticoagulants, nonsteroidal anti-inflammatory drugs, 
angiotensin II receptor antagonists, antidiabetic drugs, 
antiepileptics, and alkylating anticancer prodrugs (7–9). 
Clinically the most interesting allelic variants of CYP2C9 
are *2 and *3 (10). The *2 allele is categorised as a loss-
of-function variant, and the *3 allele as a no-function 
variant, based on data obtained from studies conducted on 
multiple substrates, including flurbiprofen, celecoxib, 
phenytoin, and warfarin (9). Accordingly, an individual’s 
ability to metabolise CYP2C9 substrates can be classified 
into the following phenotypes: normal metaboliser (*1/*1 
genotype), intermediate metaboliser (*1/*1; *1/*3; and 
*2/*2 genotype), and poor metaboliser (*2/*3 and *3/*3 
genotype) (11). Since the prevalence of poor metabolisers 
in Caucasian population is 3–5 %, genotyping of CYP2C9*2 
and *3 could be very important in initial dose adjustment 
in patients requiring anticoagulant therapy, such as warfarin 
(12, 13).
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CYP2C19 metabolises 8–10 % of commonly used drugs 
such as proton pump inhibitors, anticonvulsant drugs, 
antiplatelet drugs, and antidepressants (14, 15). Besides the 
wild-type *1 allele, the most common allelic variant is the 
loss-of-function CYP2C19*2, characterised by reduced 
enzyme activity (6, 14). Its prevalence in European 
populations is 16 %, in Africa 14 %, and in Asia 26 %.
Genotyping for the CYP2C19 allelic variant *3 is 
important in clinical practice, since its carriers have no 
ability to metabolise substrates completely, which may lead 
to drug accumulation in the body (16). Individuals carrying 
these two loss-of-function alleles (e.g. *2/*2, *2/*3, *3/*3) 
are therefore characterised as poor metabolisers (8). 
However, allelic variant *3 is very rare in Europeans and 
Africans (1 %) but not as rare in Asians (8 %) (15, 17).
In contrast to the *2 allelic variant, a recently identified 
CYP2C19*17 variant increases transcriptional activity, and 
individuals carrying one wild-type (normal function) allele 
and one gain-of-function variant (*1/*17) are categorised 
as rapid metabolisers (12, 18), whereas those carrying two 
gain-of-function variants (*17/*17) are classified as ultra-
rapid metabolisers (19). Determining whether a person is 
a carrier of the CYP2C19*17 polymorphism could therefore 
be very important in clinical practice, since clopidogrel has 
increased efficacy in these carriers and increases their risk 
of bleeding (14, 20).
Considering that no genotyping of these important allele 
variants of CYP2C9 and CYP2C19 has been conducted in 
the Republic of Srpska in Bosnia and Herzegovina, the aim 
of our study was to fill that gap and also compare our 
findings with other populations.
MATERIALS AND METHODS
Our study included 216 randomly selected Caucasian 
healthy volunteers from the general population of the 
Republic of Srpska, which is one of the federal entities 
located in the northern and eastern part of Bosnia and 
Herzegovina, with a population of about 1.2 million (21). 
The sample was recruited to reflect population distribution 
from all over the Republic of Srpska. It consisted of 114 
men (53 %) and 102 (47 %) women aged between 18 and 
78 years (median: 41). The study was approved by the Ethics 
Committee of the University of Banja Luka Faculty of 
Medicine. All participants signed informed consent forms 
before inclusion. The exclusion criteria were serious mental 
or physical illnesses. The study was performed according 
to the Declaration of Helsinki.
Genotyping
Genetic analysis was done at the Laboratory for 
Molecular Biology and Genetics of the University of Banja 
Luka Faculty of Medicine Center for Biomedical Research. 
Genomic DNA was extracted from 3–6 mL of peripheral 
blood collected in Na-EDTA tubes using PureLink® gDNA 
Blood Kit (Invitrogen, Carlsbad, CA, USA). Genotypes of 
CYP2C9 *2 (3608C>T, rs1799853), CYP2C9*3 (42164A>C, 
rs1057910 ), CYP2C19*2 (681G>A, rs4244285), 
CYP2C19*3 (17948G>A, rs4986893), and CYP2C19*17 
(-806C>T, rs12248560) were determined with real-time 
polymerase chain reaction (RT-PCR) using TaqMan® drug 
metabolism genotyping assays (C_25625805_10, 
C_27104892_10, C_25986767_70, C_469857_10, and 
C_27861809_10, respectively) according to the 
manufacturer’s instructions (Applied Biosystems, Foster 
City, CA, USA). PCR conditions included initial 
denaturation/polymerase activation at 95 °C for 10 min, 
followed by 50 two-step cycles: denaturation at 95 °C for 
15 s and annealing and extension at 60 °C for 90 s. The 
results were analysed with the Applied Biosystems 7500 
software v2.0.6 (Applied Biosystems).
Statistical analysis
Allele and genotype prevalences were estimated by gene 
counting. Genotype distributions were tested for the Hardy-
Weinberg equilibrium. Chi-squared test with Yate’s 
correction was used to test similarities or differences in 
allele distribution. For all analyses we used the Social 




As expected, the wild-type CYP2C9*1 dominated 
(78.90 %), followed by the CYP2C9*2 variant (13.66 %), 
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Table 1 Genotype and predicted phenotype prevalences of the CYP2C9 allelic variants in the population of the Republic of Srpska
 Genotype Participants (N) Prevalence (%) Confidence interval (95 %) Predicted phenotype
CYP2C9*1/*1 134 62.03 55.20–68.53 normal metabolisers
CYP2C9*1/*2 47 21.76 16.45–27.86 intermediate metabolisers
CYP2C9*1/*3 26 12.04 8.02–17.14 intermediate metabolisers
CYP2C9*2/*2 5 2.31 0.76–5.32 intermediate metabolisers
CYP2C9*2/*3 2 0.93 0.11–3.30 poor metabolisers
CYP2C9*3/*3 2 0.93 0.11–3.30 poor metabolisers
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while the prevalence of the CYP2C9*3 allele was 7.40 % 
(Table 1). All observed genotype frequencies were in the 
Hardy-Weinberg equilibrium. Accordingly, the most 
prevalent (62.03 %) were normal metabolisers (*1/*1 
genotype). Poor metabolisers (*2/*3 and *3/*3 genotype) 
accounted for 1.86 %, and intermediate metabolisers (*1/*2, 
*1/*3 or *2/*2 genotype) for 36.11 % of participants.
The prevalences of CYP2C9*2 and CYP2C9*3 alleles 
found in our study are similar to the respective ones reported 
in other European countries such as Germany (14.0 %; 
p=0.29 and 5 %; p=0.37) (20), Russia (10.5 %; p=0.16 and 
6.7 %; p=0.78) (22), Spain (16 %; p=0.36 and 10 %; p=0.25) 
(23), Greece (12.9 %; p=0.80 and 8.13 %; p=0.58) (24), 
North Macedonia (13.9 %; p=0.91 and 7.3 %; p=0.94) (17), 
Croatia (14.5 %; p=0.65 and 7.6 %; p=0.89) (8), Serbia 
(11.7 %; p=0.30 and 8.1 %; p=0.68) (25), and Slovenia 
(12.2 %; p=0.54 and 6.3 %; p=0.55) (26). However, one 
Romanian study (27) showed significantly higher 
prevalence of the *2 and *3 alleles (29 %, p<0.0001 and 
20.2 %; p<0.0001, respectively). The general prevalences 
of the CYP2C9*2 and *3 alleles in the Caucasian population 
are about 13 % (*2) and 7 % (*3) (28) but significantly 
lower in the East Asians (0.01 % and 0.3 %), Africans (2 % 
and 1 %), and African-Americans (1 % and 0.5 %) (29, 30). 
A more detailed comparison is available in Table 3.
CYP2C19
Again, the wild-type CYP2C19*1 allele was the most 
prevalent (63.43 %), followed by CYP2C19*2 (16.20 %) 
and CYP2C19*17 (20.37 %) (Table 2). The observed 
prevalence of the *2 and *17 allelic variants were within 
the European ranges (8, 18). Similar prevalences have been 
reported for the neighbouring countries. In the Serbian 
population the prevalence of the *2 allele was 16.3 % 
(p=0.97) and of the *17 allele 22.2 % (p=0.45). In the 
Croatian population it was 14.8 % (p=0.50) and 23.7 % 
(p=0.19), in the North Macedonian 14.4 % (p=0.48) and 
20.1 % (p=0.93), and in the population of Kosovo 13.03 % 
(p=0.18) and 19.01 % (p=0.61), respectively (8, 17, 25, 30). 
However, Russian and Greek studies showed a significant 
difference in the *2 allele prevalence (p=0.0002 and 
p=0.0035, respectively) (22, 24). A more detailed 
comparison is given in Table 3.
Eighty-nine participants (41.20 %) with the 
CYP2C19*1/*1 genotype were normal metabolisers, 52 
(24.07 %) with the CYP2C19*1/*2 and CYP2C19*2/*17 
genotypes were intermediate metabolisers, nine (4.17 %) 
with the CYP2C19*2/*2 genotype were poor metabolisers, 
57 (26.39 %) with the CYP2C19*1/*17 genotype rapid 
metabolisers, and nine (4.17 %) with the CYP2C19*17/*17 
genotype were ultra-rapid metabolisers. Carriers of the 
CYP2C19*17 allele are at risk of bleeding, especially the 
ultra-rapid metabolisers (carriers of the CYP2C19*17/*17 
genotype) (18). Carriers of the CYP2C19*2/*17 genotype 
are generally considered intermediate metabolisers, but 
their metabolic phenotype is difficult to predict, since some 
data suggest that CYP2C19*17 may not compensate for the 
CYP2C19*2 allele (8).
As for the CYP2C19*3 allele, none was detected in this 
study, which corresponds to other Caucasian populations 
such as Croatian, Danish, Canadian, German, Polish, and 
Australian (4, 31–35).
CONCLUSION
In summary, our data confirmed similar prevalences of 
the five CPY2C9 and CYP2C19 polymorphisms in the 
population of the Republic of Srpska with other European 
populations. Although our findings are based on a relatively 
small sample size, these data could be useful in assessing 
the risks and benefits of drug therapy in individuals 
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Table 2 Genotype and predicted phenotype prevalences of the CYP2C19 allelic variants in the population of the Republic of Srpska
Genotype Participants (N) Prevalence (%) Confidence interval (95 %) Predicted phenotype
CYP2C19*1/*1 89 41.20 34.57–48.08 normal metabolisers
CYP2C19*1/*2 39 18.05 13.17–23.85 intermediate metabolisers
CYP2C19*2/*17 13 6.02 3.24–10.07 intermediate metabolisers
CYP2C19*1/*3 - - - intermediate metabolisers
CYP2C19*3/*17 - - - intermediate metabolisers
CYP2C19*2/*2 9 4.17 1.92–7.76 poor metabolisers
CYP2C19*3/*3 - - - poor metabolisers
CYP2C19*2/*3 - - - poor metabolisers
CYP2C19*1/*17 57 26.39 20.64–32.80 rapid metabolisers
CYP2C19*17/*17 9 4.17 1.92–7.76 ultra-rapid metabolisers
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Prevalencija pet farmakološki najznačajnijih CYP2C9 i CYP2C19 alelenih varijanti u populaciji Republike Srpske 
u Bosni i Hercegovini
Citokrom P450 (CYP) visokopolimorfna je superobitelj enzima s ključnom ulogom u metabolizmu lijekova, masnih 
kiselina, steroida i ksenobiotika. U okviru spomenute skupine enzimi CYP2C9 i CYP2C19 prepoznati su kao klinički 
važni jer sudjeluju u prvoj fazi metabolizma lijekova te mogu dovesti do neadekvatnoga terapijskog odgovora, toksičnosti 
i pojave određenih bolesti. Cilj istraživanja je bio odrediti genotipove i prevalenciju alela u 216 nasumice odabranih 
zdravih ispitanika u populaciji Republike Srpske (Bosna i Hercegovina), te rezultate usporediti s drugim populacijama. 
Genotipovi enzima CYP2C9 i CYP2C19 određeni su metodom lančane reakcije polimeraze u realnom vremenu (eng. 
real-time PCR). Prema protokolu proizvođača, korištene su Taqman početnice i probe (engl. Taqman SNP genotyping 
assay). Kod CYP2C9, učestalosti alela *2 i *3 su 13,6 odnosno 7,4 %. Od 216 sudionika, njih četvero (1,86 %) spori su 
metabolizatori, a većina njih (62,03 %) normalni metabolizatori. Što se tiče CYP2C19, učestalosti alela *2 i *17 su 16,2 
odnosno 20,4 %. Od ukupnoga broja sudionika, njih devet (4,17 %) spori su metabolizatori, njih 57 (26,39 %) brzi 
metabolizatori, a devet je sudionika (4,17 %) okarakterizirano kao ultrabrzi metabolizatori. U usporedbi s podatcima o 
učestalosti genotipova i alelnih varijanti CYP2C9 i CYP2C19 u drugim europskim populacijama, dobiveni rezultati 
pokazali su veliku sličnost. Rezultati ovog istraživanja upućuju da bi određene terapije trebale uzeti u obzir utvrđene 
fenotipove CYP2C9 i CYP2C19 prilikom procjene individualnih rizika i dobrobiti primjene.
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